OncoSec Medical Inc (ONCSQ)

[guti]

Lasers, evidence that the ORR of the combination trial has not been provided, however, Dr. Pierce has presented evidence of raising TILs that might assist Keytruda into helping non responders. For that reason, the combination trial will be for patients with low TIL melanoma, who probably would not respond to Keytruda, and therefore the ORR of the Combo will not need to be greater than Keytruda alone. If it is, then Oncosec will have the upper hand in any deal.